|
Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. Clinical research trials and Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.. Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. clinical trial. Test subjects typically receive the most effective healthcare possible for their Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.  Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
For Condition: Chronic Lymphocytic Leukemia,Myelodysplastic Syndrome,Acute Myelogenous Leukemia
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: Primary Objective: To determine the safety and maximum tolerated dose of Mylotarg as part of a reduced-intensity preparative regimen patients undergoing related, mismatched-related or matched unrelated donor transplantation. Secondary Objectives: 1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy. 2. To evaluate the incidence and severity of GVHD in this population 3. To evaluate disease-free and overall survival and relapse rates.
Details: Allogeneic bone marrow transplantation is an effective first line and salvage therapy in-patients with AML, CML or MDS. In the past, allogeneic transplantation has been limited to younger patients due to the increased risk of regimen-related toxicity and graft-versus-host disease (GVHD). In order to expand the use of alloBMT to older patients, researchers at MD Anderson Cancer Center have pioneered the use of nonmyeloablative preparative therapy for allogeneic transplantation. Nonmyeloablative therapy utilizes low-dose chemotherapy in order to decrease regimen-related toxicity. The low-dose chemotherapy induces host immunosuppression, spares toxicity, and allows engraftment of donor stem cells. The goal of this therapy is to exploit the anti-tumor effects of donor immune cells. One shortcoming of nonmyeloablative transplantation is an increased risk of disease relapse, especially in patients with high-risk disease. This includes patients with relapse or refractory AML, advanced MDS and advanced CML. Mylotarg is a novel immunotoxin directed against the CD33 antigen found on most AML, CML and MDS clones. Mylotarg has been shown to have significant anti-leukemia activity with little toxicity. The goal of this Phase I/II protocol is to evaluate the safety and efficacy of adding escalating doses of Mylotarg to Fludarabine and Melphalan in patients with CML, MDS or acute myelogenous leukemia undergoing related, mismatch-related or matched unrelated donor allogeneic transplantation. The hypothesis is that Mylotarg will provide potent anti-leukemic effects without additional toxicity. Mylotarg, Melphalan, and Fludarabine have non-overlapping toxicities. A more potent anti-leukemic response may increase the complete remission rates and induce a state of minimal residual disease (MRD). Therefore, the GVL effect will have a better chance for success.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 55 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients 12-75 years of age - Patients are eligible if deemed ineligible for conventional high dose chemotherapy programs because of concurrent medical conditions. Patients with refractory AML are always eligible if ejection fraction > 35, FEV1, FVC, or DLCO > 40%, abnormal LFT's. - Patients must have recovered from previous Grade III-IV toxicity due to prior anti-neoplastic therapy (except alopecia). - Patients with the following disease categories will be eligible: a. AML with induction failure, relapse or 2nd remission b. MDS with IPI INT-2 or High-risk disease (Appendix 4) or CMML c. CML in accelerated phase or blast crisis d. Interferon or STI resistant CML not eligible for conventional stem cell transplant - Patients receiving prior BMT are eligible. If myeloablative chemoradiotherapy was used in the prior transplant patients must be >90 days from transplant. If non-myeloablative therapy was used patients must be >30 days post-transplant. - Leukemia cells must express cell surface CD33 evaluated by flow cytometry in > 20% of leukemia cells. - Patients must have an HLA-compatible related donor (6/6 or 5/6 HLA-match) capable of donating bone marrow or G-CSF stimulated peripheral blood stem cells using aphereses techniques or a 6/6 HLA matched unrelated bone marrow donor (serologic matching for Class I, molecular matching for DR?1). - Patients must have a ECOG PS<2 (Appendix 6), Cr<2.0, bilirubin <2, and (SGPT) <3x normal - Patients must have an estimated life expectancy > 3 months - Patient and donor must sign informed consent. Unrelated donors will be consented according to the National Donor Marrow Registry policy Exclusion Criteria: - uncontrolled active infection - HIV disease - pregnancy and nursing - active, uncontrolled CNS leukemia
Total Enrollment: 44
Location and Contact Information:
MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Gloria McCormick 713-745-1721
Additional Information:
Study ID Numbers: ID01-010;
Study Start Date: May 2001
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038831
Other Myelodysplastic Syndrome Studies:
1. Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
2. Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients with Acute Myelogenous Leukemia (AML)
3. Collection of Blood and Bone Marrow from Normal Volunteers and Patients for Research Purposes
4. Study of Gelonin Purging of Autologous Stem Cells for Transplantation
5. Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
Related Studies:
Other Myelodysplastic Syndrome Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
|
|
|
|
|
|
|
|
